Trial Profile

10-day Decitabine Versus Conventional Chemotherapy ("3+7") Followed by Allografting in AML Patients greater than or equal to 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Decitabine (Primary) ; Cytarabine; Daunorubicin; Etoposide; Idarubicin
Indications Acute myeloid leukaemia
Focus Therapeutic Use

04 Sep 2024 This study has been completed in Germany (Global end date: 26 Mar 2024).
20 Jun 2024 This study has been completed in Portugal , according to European Clinical Trials Database record
16 Jun 2024 This study has been completed in Lithuania, according to European Clinical Trials Database record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com